Back to Search
Start Over
T058: Safety and Dose‐Expansion Study of Combination Favezelimab (anti–LAG‐3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD‐1 Treatment.
- Source :
- HemaSphere; 2022 Supplement, Vol. 6, p27-27, 1p
- Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 25729241
- Volume :
- 6
- Database :
- Complementary Index
- Journal :
- HemaSphere
- Publication Type :
- Academic Journal
- Accession number :
- 175251684
- Full Text :
- https://doi.org/10.1097/01.HS9.0000890800.36906.bb